Ocugen, INC 8-K filings

NASDAQ

18 Mar 2024

OCGN

8-K: Ocugen Appoints Dr. Huma Qamar as Chief Medical Officer

Ocugen, Inc. has announced the appointment of Dr. Huma Qamar as its new Chief Medical Officer, effective March 18, 2024.

NASDAQ

21 Feb 2024

OCGN

Ocugen, INC

8-K: Ocugen Presents Clinical Showcase, Highlights Progress in Gene Therapy Programs

Ocugen presented a clinical showcase highlighting their gene therapy programs, including OCU400 for retinitis pigmentosa and Leber congenital amaurosis, and provided updates on their pipeline and market potential.